Document is current
Any future updates will be listed below
-
Authors
Xu, Guotai
Chhangawala, Sagar https://orcid.org/0000-0001-9626-1034
Cocco, Emiliano
Razavi, Pedram https://orcid.org/0000-0003-4236-0576
Cai, Yanyan
Otto, Jordan E
Ferrando, Lorenzo https://orcid.org/0000-0002-4025-7930
Selenica, Pier
Ladewig, Erik
Chan, Carmen
Da Cruz Paula, Arnaud
Witkin, Matthew
Cheng, Yuanming
Park, Jane
Serna-Tamayo, Cristian
Zhao, HuiYong
Wu, Fan
Sallaku, Mirna
Qu, Xuan
Zhao, Alison
Collings, Clayton K
D’Avino, Andrew R.
Jhaveri, Komal
Koche, Richard https://orcid.org/0000-0002-6820-5083
Levine, Ross L.
Reis-Filho, Jorge S. https://orcid.org/0000-0003-2969-3173
Kadoch, Cigall https://orcid.org/0000-0002-4058-5985
Scaltriti, Maurizio https://orcid.org/0000-0002-5522-1447
Leslie, Christina S. https://orcid.org/0000-0002-4571-5910
Baselga, José https://orcid.org/0000-0003-1361-4063
Toska, Eneda https://orcid.org/0000-0002-8974-9792
-
Funding
Funding for this research was provided by:
EIF | Stand Up To Cancer
- License Information
-
More Information
Article History
Received: 1 February 2019
Accepted: 21 November 2019
First Online: 13 January 2020
Competing interests
: M.Scaltriti has received research funds from Puma Biotechnology, Daiichi Sankyo, Immunomedics, TargImmune Therapeutics and Menarini Ricerche, is a cofounder of Medendi Medical Travel and is on the advisory board of Menarini Ricerche. C.K. is a scientific founder, fiduciary Board of Directors member, Scientific Advisory Board member, shareholder and consultant for Foghorn Therapeutics. R.L.L. is on the supervisory board of QIAGEN and is a scientific advisor to Loxo Oncology, Imago, C4 Therapeutics and Isoplexis, each including an equity interest. He receives research support from and consulted for Celgene and Roche, has received research support from Prelude Therapeutics and has consulted for Incyte, Novartis, MorphoSys and Janssen. He has received honoraria from Eli Lilly and Amgen for invited lectures and from Gilead Sciences for grant reviews. J.B. is an employee and shareholder of AstraZeneca, Board of Directors member of Foghorn Therapeutics and is a past board member of Varian Medical Systems, Bristol‐Myers Squibb, Grail, Aura Biosciences and Infinity Pharmaceuticals. He has performed consulting and/or advisory work for Grail, PMV Pharma, ApoGen Biotechnologies, Juno, Eli Lilly, Seragon Pharmaceuticals, Novartis and Northern Biologics. He has stock or other ownership interests in PMV Pharma, Grail, Juno, Varian Medical Systems, Foghorn Therapeutics, Aura Biosciences, Infinity Pharmaceuticals and ApoGen Biotechnologies, as well as Tango Therapeutics and Venthera, of which he is a cofounder. He has previously received honoraria or travel expenses from Roche, Novartis and Eli Lilly. P.R. has received consultation fees from Novartis and institutional research funds from Grail and Illumina. J.S.R. is a consultant of Goldman Sachs and Repare Therapeutics, a member of the Scientific Advisory Board of VolitionRx and Paige (Artificial Intelligence) and an ad hoc member of the Scientific Advisory Board of Ventana Medical Systems, Roche, Genentech, Novartis and InviCRO, outside of the scope of the submitted work. E.T. has received honoraria from AstraZeneca for invited lectures. No potential conflicts of interests were disclosed by the other authors.
